FRANCISCO JAVIER
SALMERÓN ESCOBAR
Investigador en el periodo 2002-2020
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (9)
2021
-
Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry
Journal of Hepatology, Vol. 75, Núm. 1, pp. 86-97
-
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Liver International, Vol. 41, Núm. 9, pp. 2076-2086
2020
-
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure
Antiviral Research, Vol. 174
-
Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))
Journal of Hepatology
-
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25
2019
-
Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort
Liver International, Vol. 39, Núm. 1, pp. 90-97
-
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain
PLoS ONE, Vol. 14, Núm. 11
2015
-
Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery
Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153
1995
-
Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study
Hepatology, Vol. 21, Núm. 3, pp. 674-679